I’m excited to announce that Arcadia Medicine (Arcadia Medicine) has been approved to start clinical trials in the US for AM-1002, an optimized form of MDMA developed for generalized anxiety. We will be initiating a clinical trial by year end. A huge thanks to Sam Altman Fred Ehrsam Dylan Field

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses reunionneuro.com/2025/09/30/reu…

Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) I cut losses with $CYBN and spread money around to $ATAI, $CMPS, $VTGN, $NEUP (new position), $VOO, and $VTI As always, this is not investment advice. I share to stay transparent and spark

Thank you NIH and @NIAAA for the grant to begin preclinical research for a treatment of alcohol use disorder (AUD). Psilera is grateful for this opportunity to innovate new treatment options for these patients. Read Below: prnewswire.com/news-releases/… #mindfulmedicine #AUD

Psilera Inc. Secures National Institutes of Health Grant for AUD Research prnewswire.com/news-releases/…

via Samuel Paul Douglas's newsletter.

Resolving the Massachusetts Paradox The biopharmaceutical industry’s crisis communication plan begins at home rapport.racap.com/all-stories/re… Peter Kolchinsky

What a day for $ANRO. Trimmed around 8% of the position today. Will provide updated neuropsychiatry drug development portfolio allocation later today, after market close. -Jake

Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Trimmed 8% of my $ANRO position after the big move today. Looking forward to $NEUP phase 3 data with BNC-210 in SAD, expected this month (partial exit plan already in place). I will likely

Small RCT: one dose of ketamine was enough to improve PTSD symptoms in the short-term (compared against an opioid control). The study was not large enough to compare sex-differences or variations in trauma-type.

Arcadia Medicine Announces FDA Clearance of IND Application for a Patented Form of MDMA globenewswire.com/news-release/2…

$ATAI $ARKG

Updates: Chickened out and sold $NEUP for a 60% gain. Not investment advice. -Jake

$ATAI October 2025, Corporate Presentation ir.atai.com/static-files/9…

DemeRx Awarded $1.7 Million National Institutes of Health Grant to Advance Potential First-in-Class Neuroplastogen Drug Candidate DMX-1001 for Alcohol Use Disorder (AUD) businesswire.com/news/home/2025…

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress $GHRS investor.ghres.com/news-releases/…

Psychoactive Effects of GH001 in Patients With Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomised Controlled Trial $GHRS Link: investor.ghres.com/node/8046/html

Safety and Tolerability Results From a Phase 2b, Double-Blind Trial With an Open-Label Extension of GH001 in Treatment-Resistant Depression $GHRS Link: investor.ghres.com/node/8046/html

For the next interview/video on the Psychedelic Vantage YouTube channel, you would like to see: 1. Latest trends and insights shaping the psychedelic medicine industry, from expert guests. 2. Jake’s investment portfolio updates 3. Lived experiences of psychedelic clinical